Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes underwriting agrmnt
Inv. presentation
Asset disposition
Appointed CFO
Quarterly results
Director departure
Appointed director
|
|
ARCA biopharma, Inc. (ABIO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/21/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
8-K
| Quarterly results |
| 02/24/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
8-K
| Quarterly results |
| 10/20/2022 |
8-K
| Quarterly results |
| 08/02/2022 |
8-K
| Quarterly results|
Docs:
|
"Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, August 2, 2022 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are in the process of evaluating options for creating stockholder value, including potential development of our assets, partnering and other strategic options.” In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate s..." |
|
| 06/21/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
8-K
| Quarterly results |
| 04/18/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/14/2022 |
8-K
| Quarterly results |
| 12/16/2021 |
8-K
| Quarterly results |
| 12/02/2021 |
8-K
| Quarterly results |
| 11/02/2021 |
8-K
| Quarterly results |
| 10/28/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/16/2021 |
8-K
| Quarterly results |
| 08/09/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/04/2021 |
8-K
| Quarterly results|
Docs:
|
"Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID‑19 expanded to South America • Topline data anticipated in the fourth quarter of 2021 Westminster, CO, August 4, 2021 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We continue to be encouraged with the opportunities we see in our development pipeline compounds, rNAPc2 and Gencaro. With the ASPEN-COVID-19 Phase 2b trial of rNAPc2 expanding to South America, we look forward to completing the trial and we anticipate sharing the res..." |
|
| 07/28/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/13/2021 |
8-K
| Quarterly results |
| 07/09/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 07/07/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 06/28/2021 |
8-K
| Quarterly results |
| 06/28/2021 |
8-K
| Quarterly results |
| 06/10/2021 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K
| Quarterly results |
| 05/03/2021 |
8-K
| Quarterly results |
| 04/06/2021 |
8-K
| Quarterly results |
| 03/18/2021 |
8-K
| Quarterly results |
| 02/02/2021 |
8-K
| Quarterly results |
| 12/23/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|